Anavex Life Sciences Corp. (Nasdaq: AVXL) reported disappointing results from a Phase 2a study of ANAVEX 2-73 in patients with mild-to-moderate Alzheimer's disease. Shares of the biopharmaceutical plummeted $3.03 to close at $4.46.
Anavex Life Sciences reports disappointing study results
July 27, 2016 at 18:22 PM EDT
